New combo aims to outsmart Drug-Resistant cervical cancer
NCT ID NCT06157151
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase 2 study is testing whether adding an experimental therapy called PRGN-2009 to the immunotherapy drug pembrolizumab can help shrink tumors in people with recurrent or metastatic cervical cancer that has stopped responding to pembrolizumab alone. About 24 adults with HPV-positive cervical cancer will receive injections of PRGN-2009 plus pembrolizumab every few weeks. The main goal is to see how many patients experience tumor shrinkage.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
PRGN-2009 (a vaccine-like therapy) combined with pembrolizumab (an immunotherapy drug)
What this could lead to
If successful, this combination could shrink tumors or slow cancer growth in patients whose cervical cancer has stopped responding to standard immunotherapy.
What could go wrong
This is a small, early-phase study with only 24 participants, so results may not apply to all patients. Side effects from the combination could be serious, and the treatment may not work for everyone.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CERVICAL CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
National Institute of Health
RECRUITINGBethesda, Maryland, 20892, United States
Contact Email: •••••@•••••
-
University of Arkansas for Medical Sciences
RECRUITINGLittle Rock, Arkansas, 72205, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
University of Washington
RECRUITINGSeattle, Washington, 98109, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••